CurrentBlue Cross Blue Shield - MassachusettsPolicy 075

Hematopoietic Cell Transplantation for Multiple Myeloma and POEMS Syndrome

Medical necessity and authorization guidance for autologous and allogeneic hematopoietic cell transplantation for multiple myeloma and POEMS syndrome for commercial members of Blue Cross Blue Shield Massachusetts.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyHematopoietic Cell Transplantation for Multiple Myeloma and POEMS Syndrome

Policy CodePolicy 075

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit initial authorization requests using Authorization Manager with facility and servicing provider NPIs and include clinical documentation that meets medical policy guidelines.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

075policy number

multiple RCTsevidence for autologous HCT

insufficientallo-HCT evidence

Prior authPA required

≈14 yrs

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Hematopoietic Cell Transplantation

Coverage statements for Multiple Myeloma and POEMS

Covered when ALL of the following statements in the policy apply

Autologous HCT for Multiple Myeloma: A single or second (salvage) autologous hematopoietic cell transplantation may be MEDICALLY NECESSARY to treat multiple myeloma.

from policy

Tandem autologous-autologous HCT for Multiple Myeloma: Tandem autologous-autologous hematopoietic cell transplantation may be MEDICALLY NECESSARY to treat multiple myeloma in individuals who fail to achieve at least a near-complete or very good partial response after the first transplant in the tandem sequence.failure to achieve >= near-complete response or very good partial response (VGPR)

near-complete and VGPR definitions per EBMT

Autologous followed by reduced-intensity allogeneic HCT (tandem): Tandem transplantation with an initial autologous HCT followed by a non–marrow-ablative (reduced-intensity conditioning) allogeneic HCT may be MEDICALLY NECESSARY to treat individuals with newly diagnosed multiple myeloma.

policy allows reduced-intensity tandem approach

Allogeneic HCT for Multiple Myeloma: Allogeneic hematopoietic cell transplantation, myeloablative or nonmyeloablative, as upfront therapy of newly diagnosed multiple myeloma or as salvage therapy, is INVESTIGATIONAL.

not covered/experimental stance

Autologous HCT for POEMS syndrome: Autologous hematopoietic cell transplantation may be considered MEDICALLY NECESSARY to treat disseminated POEMS syndrome (eg, diffuse sclerotic lesions or marrow involvement).disseminated disease

policy statement

Allogeneic and tandem HCT for POEMS: Allogeneic and tandem hematopoietic cell transplantation are INVESTIGATIONAL to treat POEMS syndrome.

not covered/experimental stance

Medically necessary indications

Covered when evidence shows improved net health outcome in these clinical contexts:

Newly diagnosed multiple myeloma: Autologous HCT as initial treatment or consolidation improves overall survival or progression-free survival compared with conventional chemotherapy or regimens without transplant; evidence includes randomized controlled trials and systematic reviews.

Supported by multiple RCTs and systematic reviews (see chunk 24).

Tandem autologous HCT (newly diagnosed): Tandem autologous HCT has shown improved overall or recurrence-free survival in several randomized trials, but results are inconsistent across studies; may be considered in select patients based on trial data and clinical judgment.

Conflicting trial results referenced (see chunk 24 and 27).

Relapsed or refractory multiple myeloma: Second (salvage) autologous HCT improves overall survival compared with conventional chemotherapy in patients who relapse after a first autologous HCT; tandem autologous HCT can improve overall survival in refractory settings.

Supported by RCTs and reviews (see chunk 27).

Insufficient evidence / investigational

Situations with insufficient or mixed evidence:

Allogeneic HCT as initial or salvage therapy for multiple myeloma: Nonrandomized studies report outcomes for myeloablative and reduced-intensity conditioning (RIC) allogeneic HCT, but convincing evidence is lacking that allo-HCT improves survival better than autologous HCT; nonmyeloablative allo-HCT may have lower transplant-related mortality but higher relapse risk.

Evidence insufficient to determine net health outcome (see chunk 26).

The policy states that allogeneic hematopoietic cell transplantation (allo-HCT) as upfront or salvage therapy for multiple myeloma is considered investigational. For POEMS syndrome, autologous HCT may be medically necessary for disseminated disease (for example, diffuse sclerotic lesions or marrow involvement), whereas allogeneic and tandem HCT for POEMS are described as investigational.

There is no enumerated exclusion list in the extracted text; however, the policy notes that evidence is insufficient to show that allo-HCT provides a survival advantage over autologous HCT and that allo-HCT is associated with higher transplant-related mortality in some studies. As a result, allogeneic HCT may be restrictedinvestigational.

The reference section citations are provided for background and guideline context, and do not list explicit coverage exclusions within the extracted reference entries.

The document distinguishes conventional myeloablative conditioning from reduced-intensity or nonmyeloablative approaches. Reduced-intensity (nonmyeloablative) allo-HCT is associated with lower transplant-related mortality but a higher risk of relapse; published evidence includes variable outcomes for both myeloablative and RIC regimens and is insufficient to establish a clear survival benefit of allo-HCT over autologous HCT.

Within the extracted sections there are no explicit statements phrased as 'not medically necessary.' The policy instead characterizes certain uses (for example, allo-HCT as upfront or salvage therapy for multiple myeloma, and allogeneic or tandem HCT for POEMS) as investigational, and notes insufficient evidence for routine use of nonmyeloablative allo-HCT as first-line therapy.

Candidate Eligibility and Selection Considerations

Candidate criteria

Eligibility statements present in policy

Multiple Myeloma - autologous transplant: Candidates include patients with multiple myeloma for whom single or salvage autologous HCT is considered clinically appropriate.

policy provides general medical necessity statement (chunk 4).

Multiple Myeloma - tandem autologous: Consider tandem autologous-autologous transplant for patients who fail to achieve at least a near-complete response or very good partial response after the first transplant.failure to achieve >= near-complete response or VGPR

response-based trigger; definitions provided in policy (chunk 4).

POEMS - autologous transplant: Autologous HCT may be considered medically necessary for disseminated POEMS syndrome (eg, diffuse sclerotic lesions or marrow involvement).

Contraindications and Fitness for Transplant

A stated contraindication is inadequate medical fitness for high-intensity conditioning: patients must be sufficiently medically fit to tolerate intense conditioning regimens (myeloablative conditioning); otherwise they may be at unacceptable risk for treatment-related morbidity and organ failure and therefore not appropriate candidates for transplant.

Pretransplant Evaluation and Documentation Requirements

Prior Authorization

Prior Authorization / Authorization Guidance

Prior authorization: The policy does not explicitly list a prior authorization requirement or a formal authorization/denial criterion for hematopoietic cell transplantation (HCT) in the provided references. Providers should verify plan-specific prior authorization rules in Authorization Manager or the payer's provider portal before initiating transplant workups because clinical documentation meeting medical policy guidelines must be submitted with any authorization requests.

Verify prior authorization requirements in Authorization Manager or the payer portal before scheduling evaluation or transplant.
If an authorization request is submitted, include the clinical documentation elements listed below to support medical necessity review.

Billing Rule

Coding and Medical Necessity

Actions Required by Providers

Prior Authorization

Use Authorization Manager for initial authorization requests

Initial authorization requests for services described in this policy must be submitted using Authorization Manager and must meet the medical policy guidelines for commercial members.

Enter the facility NPI/provider ID where services will be performed.
Enter the servicing surgeon’s NPI/provider ID (not the billing group).

Prior Authorization

Obtain outpatient prior authorization via Authorization Manager

Outpatient prior authorization is required for all commercial products effective 1/1/2019; Authorization Manager is the means clarified in policy history for submitting requests and supporting documentation.

Applies to Commercial Managed Care (HMO/POS), Commercial PPO, and Indemnity outpatient services.
Authorization Manager is available 24/7 for submission and document upload.

Billing and Coding

Covered CPT CodesCPTCovered

38241

Bone marrow or blood-derived peripheral stem-cell transplantation; autologous

Investigational CPT CodesCPTExperimental

38240

Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic

Covered HCPCS CodesHCPCSCovered

S2150

Bone marrow or blood-derived peripheral stem-cell (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications including pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post- transplant care in the global definition

Investigational HCPCS CodesHCPCSExperimental

S2142

Cord blood-derived stem-cell transplantation, allogeneic

Coding history notes (no explicit codes in this extract)mixed

No codes listed

Age threshold references

Age references in evidenceSystematic reviews and trials include analyses of older patients (age ≥65) in some studies; however, this policy extract does not specify any numeric coverage age thresholds.

No coverage age cutoff specifiedThe document does not define an explicit age-based eligibility limit for autologous or allogeneic HCT in this extract.

Clinical selection considers fitness, not age aloneCandidate selection emphasizes medical fitness for conditioning intensity rather than a strict age threshold.

Post-Transplant Care and Coverage

Post-transplant immunosuppression and infectious disease monitoring

Post-allo-HCT immunosuppression requiredImmunosuppressant drugs are required after allogeneic HCT to minimize graft rejection and graft-versus-host disease; monitoring for opportunistic infections is clinically required.

Specific agents and durations not specifiedThis extract does not delineate specific immunosuppressive drugs, doses, or durations for coverage purposes.

Monitoring expectationsPatients undergoing allo-HCT are susceptible to opportunistic infections during the period of immunosuppression; clinical monitoring is implied as necessary though specifics are not provided.

Definitions

Near-complete response

Definition (EBMT)Near-complete response: disappearance of M protein at routine electrophoresis but positive immunofixation (European Group for Blood and Marrow Transplant definition).

Context for useTandem autologous-autologous HCT may be considered for individuals who fail to achieve at least a near-complete response after the first transplant in the sequence.

Implication for coverage decisionsFailure to attain near-complete response is a response-based trigger in policy for considering tandem transplantation.

Very good partial response (VGPR)

DefinitionVery good partial response (VGPR): approximately a 90% decrease in the serum paraprotein level.

Role in tandem transplant decisions

Facility and Center Requirements

Prior Authorization

Precertification/preauthorization required for inpatient procedures

Precertification/preauthorization is required for inpatient procedures as stated in the policy; use Authorization Manager to request authorization for inpatient services.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyHematopoietic Cell Transplantation for Multiple Myeloma and POEMS Syndrome

Policy CodePolicy 075

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit initial authorization requests using Authorization Manager with facility and servicing provider NPIs and include clinical documentation that meets medical policy guidelines.

SourceLink

On This Page

POEMS syndrome with disseminated disease: Autologous HCT may improve outcomes for patients with disseminated POEMS syndrome based on retrospective cohort studies, case series, and case reports; considered appropriate to treat the underlying plasma cell clone when disease is disseminated.

Evidence limited to observational data (see chunk 28).

disseminated disease

policy text (chunk 5).

Candidate selection considerations

Candidate considerations referenced in the clinical discussion:

Disease status for autologous HCT: Autologous HCT is typically performed as consolidation when the patient's disease is in remission or has responded to initial therapy; documentation of disease status is expected for authorization.

Autologous HCT as consolidation after response described in chunk 24; documentation expectations referenced in clinical context (chunks 19,24).

HLA compatibility for allogeneic HCT: An acceptable donor should match the patient at all or most HLA loci; HLA typing is required to establish compatibility prior to allo-HCT.

HLA matching and typing described in chunk 19.

Documentation and coding: Complete clinical documentation should demonstrate medical necessity and fitness for the chosen conditioning regimen. Include relevant ICD-10 and procedure codes on authorization and claims; confirm coding aligns with the documented HCT type (autologous vs allogeneic) and approach (bone marrow, peripheral blood, cord blood). Failure to provide sufficient documentation of HLA typing, conditioning regimen details, or medical fitness may result in denial or request for additional information.

Document HCT type (autologous vs allo-HCT) and stem cell source (bone marrow, peripheral blood, cord blood).
Include ICD-10 diagnoses justifying transplant and CPT/HCPCS procedure codes for HCT and associated procedures.
Ensure medical necessity is supported by clinical notes, test results, and treatment history to reduce denial risk.

Documentation Required

Required Clinical Documentation Elements

Suggested pretransplant evaluation elements: For all patients and specifically for allo-HCT candidates, include HLA typing and compatibility assessment; a comprehensive medical fitness evaluation to determine tolerance for conditioning intensity; explicit documentation of the planned conditioning regimen (agents, doses, radiation if used); infection screening and organ function testing; and prior therapy history and disease status (e.g., remission status for autologous HCT).

HLA typing/results and donor match status for allo-HCT.
Assessment of cardiopulmonary, hepatic, renal function, and performance status to justify conditioning intensity.
Detailed conditioning regimen (agents, doses, radiation parameters) and rationale.
Current disease status and prior therapies (e.g., remission status for autologous HCT).
Infection screening results and immunization or prophylaxis plans where applicable.

Step Therapy

Step-Therapy / Treatment Sequence Context

Step-therapy and utilization context: While step-therapy is not typically applicable to HCT itself, ensure that prior lines of therapy, treatment failures, or remissions are clearly documented when transplant is being considered as consolidation or salvage therapy. This clinical history may be required to establish medical necessity and fit within the payer's coverage pathway.

Document prior systemic therapies, responses, and rationale for proceeding to HCT (e.g., consolidation after complete remission for autologous HCT).
If the plan requires evidence of prior therapies or treatment sequencing, include timelines and outcomes in the submission.

Note

No explicit PA code lists in reference sections

The policy references do not include an explicit list of prior authorization codes or detailed PA rules in the cited reference sections.

Billing Rule

Use current CPT/HCPCS/ICD codes and meet medical necessity

Report services using the most up‑to‑date CPT, HCPCS, and ICD codes and ensure the medical necessity criteria in this policy are met for those codes to be covered.

Inclusion of a code in the policy does not by itself guarantee coverage; member contract benefits apply.
Use appropriate modifiers and current industry-standard codes.

Step Therapy

No explicit step‑therapy mandate in policy extract

The evidence discussion describes autologous HCT as consolidation after response to initial therapy and compares tandem or allo‑HCT strategies with novel-agent regimens, but the policy does not impose a step‑therapy algorithm in this extract.

No explicit step‑therapy mandate (eg, required trial of specific systemic agents) is specified in the policy text provided.

Note

Provider action placeholder

—

Prior Authorization

Authorization submission must include NPIs and supporting clinical documentation

Submit initial authorization requests using Authorization Manager and include facility and servicing provider NPIs; attach clinical documentation that supports medical necessity per policy.

Facility NPI/provider ID for where services will be performed.
Servicing surgeon’s NPI/provider ID (not billing group).
Attach relevant clinical records demonstrating eligibility and disease status.

Documentation Required

Include these documentation elements with authorization requests

Documentation should specify whether the transplant is autologous or allogeneic, include HLA typing results for allo‑HCT, detail the conditioning regimen (myeloablative vs reduced‑intensity), and provide the patient’s disease status/history to support medical necessity.

Transplant type (autologous vs allogeneic).
HLA typing for donor‑recipient compatibility when allo‑HCT is planned.
Conditioning regimen type and intensity (myeloablative vs RIC).
Evidence of disease status (eg, remission prior to autologous HCT when used as consolidation).

Note

Provider action placeholder referencing references

—

Denial Risk

Precertification required for inpatient services — risk of denial if not obtained

Failure to obtain precertification/preauthorization for services performed inpatient may result in denial of coverage.

Denial Risk

Outpatient prior authorization required — risk of denial if not obtained

Failure to obtain prior authorization for outpatient hematopoietic cell transplantation for commercial managed care, PPO, and indemnity plans may lead to denial.

Denial Risk

Outpatient PA requirement in effect since 1/1/2019 — follow Authorization Manager process

Outpatient prior authorization has been required for all commercial products effective 1/1/2019; not following the prior authorization process (eg, Authorization Manager) noted in policy history could trigger denial.

Note

No additional authorization/denial criteria in reference sections

The policy text states prior authorization processes are referenced in policy history, but the cited reference sections do not include additional explicit authorization or denial criteria.

Tandem autologous-autologous HCT may be medically necessary for individuals who fail to achieve at least VGPR after the first transplant in the tandem sequence.

Use in candidate assessmentVGPR is used as a response threshold to guide consideration of additional transplant interventions in policy.

Autologous hematopoietic cell transplantation (autologous HCT)

DefinitionAutologous HCT: transplantation using hematopoietic stem cells obtained from the patient.

Source of cellsStem cells may be harvested from the patient's bone marrow, peripheral blood, or umbilical cord blood in general practice.

Clinical contextAutologous HCT is typically performed as consolidation therapy when a patient's disease is in complete remission or has responded to initial therapy.

Allogeneic hematopoietic cell transplantation (allo-HCT)

DefinitionAllogeneic HCT: transplantation using hematopoietic stem cells obtained from a donor.

HLA compatibility requirementImmunologic compatibility between donor and patient is critical and is established by HLA typing (eg, HLA-A, -B, -DR loci); an acceptable donor will match at all or most HLA loci.

Infectious and immunologic considerationsAllo-HCT recipients require immunosuppression posttransplant and are at increased risk for opportunistic infections and graft-versus-host disease.

Reduced-intensity conditioning (RIC)

DefinitionReduced-intensity conditioning (RIC): pretransplant regimens that use lower doses of cytotoxic drugs or less intense radiotherapy than traditional myeloablative conditioning, intended to reduce treatment-related morbidity while permitting graft-versus-malignancy effects.

Regimen variabilityRIC definitions and intensities are variable and tailored to disease and patient condition, ranging from nearly myeloablative to minimally myeloablative approaches.

Clinical goalRIC seeks to balance relapse risk from residual disease against nonrelapse mortality due to conditioning toxicity.

Tandem autologous transplantation

DefinitionTandem autologous transplantation: two sequential autologous hematopoietic stem cell transplants.

Evidence baseTandem transplants have been compared in multiple randomized trials and systematic reviews/meta-analyses with mixed results, informing selective use in policy.

Policy triggerPolicy allows tandem autologous-autologous HCT for patients who fail to achieve at least near-complete response or VGPR after the first transplant.

Salvage transplant

DefinitionSalvage transplant: a subsequent (second) hematopoietic cell transplantation used as therapy for relapsed multiple myeloma after a prior autograft.

Coverage stanceA single or second (salvage) autologous HCT may be medically necessary to treat multiple myeloma.

Supporting evidenceEvidence from randomized trials, reviews, and systematic reviews supports use of second autologous HCT in relapsed or refractory MM in select patients.